SAN ANTONIO (EGMN) - A switch to letrozole for breast cancer patients intolerant to anastrozole-associated musculoskeletal pain enabled nearly 90% of them to continue on adjuvant aromatase inhibitor therapy with significantly improved quality of life in an open-label prospective study. The study involved 261 postmenopausal women with hormone receptor-positive early-stage breast cancer who discontinued anastrozole (Arimidex) because of grade 2/3 arthralgia and/or myalgia. After a 2- to 3-week washout...